Minocycline hydrochloride
( DrugBank: Minocycline, Minocycline hydrochloride / KEGG DRUG: Minocycline hydrochloride, Minocycline, Minocycline hydrochloride, Minocycline )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 3 |
| 201 | Angelman syndrome | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
| 299 | Cystic fibrosis | 1 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
201. Angelman syndrome
Clinical trials : 33 / Drugs : 32 - (DrugBank : 13) / Drug target genes : 22 - Drug target pathways : 21
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
206. Fragile X syndrome
Clinical trials : 118 / Drugs : 75 - (DrugBank : 30) / Drug target genes : 58 - Drug target pathways : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
299. Cystic fibrosis
Clinical trials : 1,826 / Drugs : 1,271 - (DrugBank : 246) / Drug target genes : 118 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|